Back
ATVR
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Activeport Group Ltd
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Growth
11 months capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Activeport Group Ltd - Rights - Applications Close 01-Nov-2024
π Performance
Price History
0.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.00
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in ATVR
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in ATVR
N/A
ATVR investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in ATVR also invest in...
IVV
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
π Performance (5Yr p.a)
22.57%
π Share price
$65.86 AUD
π HIGH PRICE GROWTH
πΊπΈ UNITED STATES
Argo Investments Ltd is a AU-based company operating in industry. The company is headquartered in Adelaide, South Australia. Argo Investments Limited is an investment company. The principal activities of the Company include the investment of funds in Australian listed securities and short-term interest-bearing securities. The Companyβs objective is to maximize long-term shareholder returns through reliable fully franked dividend income and capital growth. Its investment portfolio comprises approximately 85 Australian companies from across a range of industries. The firm invests in various sectors, including other financials, materials, banks, healthcare, consumer staples, energy, property, listed investment companies, and utilities. Its subsidiaries include Argo Investments Limited (parent entity) and Argo Service Company Pty. Ltd.
π Performance (5Yr p.a)
4.72%
π Share price
$9.33 AUD
Classic Minerals Ltd. engages in exploration of mineral resource-based projects, focusing on gold and nickel. The firm holds approximately 578 square kilometers of tenements across two regional exploration areas in minerals-rich West Australia. The company is focused on gold deposits in Western Australia's Goldfields region at Forrestania and Kat Gap. Its flagship Kat Gap Gold Project is located approximately 170 kilometers (km) south of Southern Cross and also 50 km south of the Company's Forrestania Gold Project. The Forrestania Gold Project is located approximately 120 km south of Southern Cross, Western Australia and contains the Lady Ada and Lady Magdalene deposits. Its Fraser Range Project (E28/1904) is approximately 40 km to the northeast of Sirius Nova deposit on the Fraser-Albany Mobile Belt, approximately 160 km east southeast of Kambalda and is of interpreted Proterozoic age. The company holds approximately 28 km of strike across 84 square kilometers.
π Performance (5Yr p.a)
-9.62%
π Share price
$0.00 AUD
βοΈ MINING
Genesis Minerals Ltd. engages in the exploration and development of gold deposits in Western Australia. The company is headquartered in Perth, Western Australia and currently employs 603 full-time employees. The company went IPO on 2007-08-02. The firm's principal activities are gold mining, project development and exploration activities in Western Australia. Its operations include Leonora Operations and Laverton Operations. The firm's Leonora Operations include Admiral Operations, Gwalia Operations, Harbour Lights Project, Tower Hill Project and Ulysses Operations. The Gwalia Gold Mine is located at Gwalia, a few kilometers south of Leonora, Western Australia. Its Laverton Operations include Bruno-Lewis Project, Jupiter Project, Laverton Gold Project and Redcliffe Project. The Bruno-Lewis project is located within the northeastern goldfields in the Archaean Yilgarn Block. The Redcliffe Project includes the Redcliffe, Hub, GTS, Nambi, Kelly, Bindy and Mesa Westlode deposits. Genesis Mining Services is the inhouse mining services provider for the Company, providing Open Pit mining services.
π Performance (5Yr p.a)
109.76%
π Share price
$5.45 AUD
βοΈ MINING
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
17.41%
π Share price
$147.54 AUD
π GLOBAL
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
Want more shares? Try these...
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
π Performance (5Yr p.a)
2.38%
π Share price
$0.15 AUD
𧬠BIOTECHNOLOGY